Selenium and selenomethionine levels in prostate cancer patients
Selenium and selenomethionine levels in prostate cancer patients
复制标题
DOI：
10.1016/j.cdp.2003.11.002
复制
发表时间：
2004-01-01
影响因子：
--
通讯作者：
Gandolfi, AJ
中科院分区：
文献类型：
--
作者：
Nyman, DW;Stratton, MS;Gandolfi, AJ
目的：硒（Se）和硒代蛋氨酸（Se- met）已被确定为潜在的前列腺癌化学预防药物。采用硒氨基酸的物种形成（分离和鉴定）和定量分析方法，对前列腺癌患者血清和前列腺组织中的硒met进行了分析。测定了总硒含量。方法：采用高效液相色谱-离子通道等离子体质谱（HPLC - ms）对血清和前列腺组织标本进行分析。样本由25名接受根治性前列腺切除术治疗前列腺癌的受试者提供。结果：血清Se-Met平均浓度为59.4 +/- 19.5 ng/ml。平均血清总硒水平为133.8±29.2 ng/ml。还比较了来自前列腺过渡区和外周区成对样品中的总硒水平。外周区组织总平均硒含量高于过渡区组织（0.432 +/- 0.212 mg /g比0.293 +/- 0.172 mg /g, P = 0.01）。Se-Met在大多数前列腺组织中检测到。结论：本组前列腺癌患者血清和前列腺组织总硒水平在正常硒摄入量范围内。外周组织总硒水平明显高于过渡带组织。这是首次在前列腺组织中检测到Se-Met。(C) 2004国际预防肿瘤学会。Elsevier Ltd.出版。版权所有。
Objective: Selenium (Se) and selenomethionine (Se-Met) have been identified as potential chemopreventive agents of prostate cancer. Using an assay for the speciation (separation and identification) and quantification of selenoamino acids, Se-Met was profiled in serum and prostate tissue from prostate cancer patients. Total Se was measured also. Methods: Serum and prostate tissue samples were analyzed using high performance liquid chromatography ion channel plasma-mass spectrometry (HPLC ICP-MS). Samples were provided by 25 subjects undergoing radical prostatectomy for the treatment of prostate cancer. Results: The mean serum Se-Met concentration was 59.4 +/- 19.5 ng/ml. Mean total serum Se levels were 133.8 +/- 29.2 ng/ml. Total Se levels in paired samples from the transitional and peripheral zones of the prostate were also compared. Total mean Se levels in peripheral zone tissue was higher than in transitional zone tissue (0.432 +/- 0.212 mug/g versus 0.293 +/- 0.172 mug/g, P = 0.01). Se-Met was detected in the majority of prostate tissues. Conclusion: This group of prostate cancer patients had total Se levels in serum and in prostate tissue in a range expected for normal Se intake. There was a significantly higher total Se level found in peripheral versus transitional zone tissues. This is the first time that Se-Met has been detected in prostate tissue. (C) 2004 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved.